Key facts
- It has raised $5.1M across 3 recorded rounds; the latest was Seed Round ($796K) in Apr 2025.
- Notable investors include Althea Group (New York), Cedars-Sinai Accelerator, CitySide Ventures, Coyote Ventures, Ignite Healthcare Network — 10 tracked in total.
- Hera Biotech has filed 6 Form Ds with the SEC since 2020, most recently Sep 2025 ($796K sold to 8 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Hera Biotech
Funding rounds
3 roundsAbout Hera Biotech
Developer of definitive tissue-based tests designed to diagnose and stage endometriosis. The company's technology is a novel non-surgical method for the early diagnosis of endometriosis, enabling medical community to address therapeutic deficiencies in women.
- Sector
- Healthcare
- HQ
- San Antonio, TX, United States
- Founded
- 2020
- Employees
- 8
- Website
- herabiotech.com/
- Ownership
- Privately Held (backing)
Hera Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Hera Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Hera Biotech in its N-PORT filings yet. We sweep new filings monthly.